Zentiva, a.s.
The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.
Business. 1SKF401E.BV is a pharmaceutical company operating within the Healthcare sector, specifically engaged in pharmaceuticals and medical research. The firm generates revenue through the sale of products, with key performance indicators including pipeline depth, research and development expenditure, and price realization. No specific operating segments or geographic breakdowns are provided in the available data. The company is identified by the ticker 1SKF401E.BV, though specific exchange listing details are not specified.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
1SKF401E.BV is a pharmaceutical company operating within the Healthcare sector, specifically engaged in pharmaceuticals and medical research. The firm generates revenue through the sale of products, with key performance indicators including pipeline depth, research and development expenditure, and price realization. No specific operating segments or geographic breakdowns are provided in the available data. The company is identified by the ticker 1SKF401E.BV, though specific exchange listing details are not specified.
The company maintains a strong liquidity position, with a current ratio of 5.9, indicating a significant buffer of current assets over current liabilities. The absence of long-term debt and a debt-to-equity ratio of 0.0 further reinforce the company's conservative capital structure. However, the free cash flow is negative at -17.174 million EUR, suggesting that the company is currently investing more in operations than it is generating in cash.
Profitability metrics show the company is performing well relative to industry norms. The return on equity (ROE) is 15.67%, and the return on assets (ROA) is 12.84%, both of which are strong indicators of efficient use of equity and assets. The operating margin, calculated as operating income divided by revenue, is 29.35%, which is a high margin and suggests strong cost control and pricing power.
The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. There is no geographic breakdown provided, but the company's operations are likely centered in its home market, given the lack of international revenue disclosure.
The company's growth trajectory is positive, with a revenue of 113.242 million EUR in the latest period. While no forward-looking revenue guidance is provided, the strong operating income and gross profit suggest a stable and potentially growing business. The capital expenditure of -4,000 EUR indicates minimal investment in new assets, which may suggest a focus on maintaining existing operations rather than expansion.
The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The absence of long-term debt and the strong current ratio support the low liquidity risk assessment. The dilution risk is also low, as the number of shares outstanding is the same for both basic and diluted shares, indicating no potential for share dilution.
Recent events include the latest actual EPS of 149.00 EUR and revenue of 5,092.00 million EUR, as reported by analysts. These figures suggest strong performance in the most recent reporting period and may indicate a positive trend in earnings and revenue.
- The company has a strong liquidity position with a current ratio of 5.9 and no long-term debt.
- Profitability is robust, with a return on equity of 15.67% and a return on assets of 12.84%.
- The company's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
- The company is currently experiencing negative free cash flow, indicating a net outflow of cash from operations.
- The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- 1SKF401E.BV Market data — financials · 2026-05-26
- Zentiva as Market data — analyst estimates · 2026-05-26